Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival
Company leadership is framing the move as transformational.
ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA
71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
Hands-on clinical workshop in Bengaluru brings together neurologists, ENT specialists and physicians
The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
